Gilead to Buy Cancer Drugmaker for $21 Billion
The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
Akorn Files for Chapter 11 After Failed Takeover
The generic drugmaker listed $10 billion of debt and $10 billion of assets.
Gilead to Invest $5B in Galapagos Partnership
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
Merck Agrees to Buy Peloton Therapeutics
The privately held cancer drugmaker had been set for a public offering Wednesday.
Pfizer Beats Estimates on Strength in Key Drugs
Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
Novartis to Buy AveXis in $8B Gene Therapy Bet
The deal gives the Swiss drugmaker a neurological disease treatment that may have "a multi-billion dollar peak sales potential."
Teva to Cut 14,000 Jobs in ‘Drastic’ Overhaul
The drugmaker says "there is no alternative" to its restructuring plan amid pricing pressure on its core generics business.
Lilly Veteran Josh Smiley Promoted to CFO
Smiley takes over from Derica Rice amid a cost-cutting push aimed at freeing up cash for Lilly to invest in developing new drugs.
Alexion to Cut 20% of Workforce, Move HQ
The drugmaker is restructuring as it tries to rebuild its drug pipeline amid investigations of its sales practices.